Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients-Reference-Cited by-同舟云学术

Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients

Author:

Bhusari Priya¹²,Vatsa Rakhee¹²,Singh Gurpreet³,Parmar Madan¹,Bal Amanjit⁴,Dhawan Devinder K.²,Mittal Bhagwant R.¹,Shukla Jaya¹

Affiliation:

1. Department of Nuclear Medicine & PET; PGIMER; Chandigarh India

2. Centre for Nuclear Medicine, Punjab University; Chandigarh India

3. Department of General Surgery; PGIMER; Chandigarh India

4. Department of Histopathology; PGIMER; Chandigarh India

Funder

Department of Science and Technology, India (INSPIRE fellowship)

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference27 articles.

1. Clinical outcome of adjuvant endocrine treatment according to Her2/neu status in breast cancer;James;Indian J Med Res,2011

2. Factors associated with HER2 overexpression in breast cancer: experience in an Asian developing country;Tan;Asian Pacific J Cancer Prev,2009

4. Radioimmunotherapy with tositumomab and iodine-131tositumomab for non-Hodgkin's lymphoma;Andemariam;Biologics,2007

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

3. Theranostics in breast cancer;Frontiers in Nuclear Medicine;2023-08-04